Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. (ITCI) Stock Overview
Explore Intra-Cellular Therapies, Inc.’s financial performance, market position, analyst ratings, and future outlook.
ITCI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Intra-Cellular Therapies, Inc. (ITCI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $129.26.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -182.12 and a market capitalization of 14B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Dr. Sharon Mates Ph.D.
860
430 East 29th Street, New York City, NY
2014